Research Article
Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag
Table 5
Results of univariable analysis of the number of drug lines and progression-free survival.
|